King® Guide to Parenteral Admixtures®
Past Updates

Summer 2017

In this supplement we added new stability information for these existing drug monographs: BUSULFAN, CARBOPLATIN, CISPLATIN, CLADRIBINE, CYTARABINE, DACARBAZINE, DACTINOMYCIN, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, HYDROCORTISONE SODIUM PHOSPHATE, IDARUBICIN HYDROCHLORIDE, IFOSFAMIDE, METHOTREXATE, MITOMYCIN, MITOXANTRONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, PENTOSTATIN, TOPOTECAN HYDROCHLORIDE, VINBLASTINE SULFATE, VINCRISTINE SULFATE, and VINORELBINE TARTRATE.

In addition new compatibility information is reported for over 40 existing drug monographs, including entries for PIPERACILLIN AND TAZOBACTAM with VANCOMYCIN HYDROCHLORIDE, ABCIXIMAB with six other drugs, CLONAZEPAM with six other drugs, HALOPERIDOL LACTATE with thirteen other drugs, OMEPRAZOLE HYDROCHLORIDE with five other drugs, and TIROFIBAN HYDROCHLORIDE with seven other drugs.

Spring 2017

In this supplement we added new drug monographs with stability and compatibility data for these drugs: BLINATUMOMAB, BRIVARACETAM, ERIBULIN MESYLATE, FERRIC CARBOXYMALTOSE, DECITABINE, FOMEPIZOLE, GLOBULIN, IMMUNE (HUMAN) AND HYALURONIDASE, IBANDRONATE SODIUM, IDARUCIZUMAB, ISAVUCONAZONIUM SULFATE, RASBURICASE, SODIUM FERRIC GLUCONATE COMPLEX, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM NITRITE, TEMOZOLOMIDE, VINCRISTINE SULFATE LIPOSOME, and ZOLEDRONIC ACID.

Also, we added new stability information for these existing drug monographs: AZTREONAM, BACLOFEN, BUSULFAN, CARBOPLATIN, CEFPIROME SULFATE, CEFEPIME HYDROCHLORIDE, CEFTAZIDIME, DORIPENEM, FENTANYL CITRATE, HEPARIN SODIUM, HETASTARCH, KETAMINE HYDROCHLORIDE, LEVETIRACETAM, MEROPENEM, NITROPRUSSIDE SODIUM, PACLITAXEL, PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM, TACROLIMUS, TRANEXAMIC ACID, and VANCOMYCIN HYDROCHLORIDE.

In addition new compatibility information is reported for over 20 existing drug monographs, including entries for CEFTOLOZANE AND TAZOBACTAM, IRINOTECAN HYDROCHLORIDE, TEDIZOLID PHOSPHATE, and SUGAMMADEX.

Winter 2016

In this supplement we added new drug monographs for CEFTAZIDIME AND AVIBACTAM, CEFTOLOZANE AND TAZOBACTAM, and SUGAMMADEX.

Also, we added new stability information for these drugs:  AMPICILLIN SODIUM, LABETALOL HYDROCHLORIDE, PIPERACILLIN AND TAZOBACTAM, POLYMYXIN B SULFATE, and PROPAFENONE HYDROCHLORIDE.

In addition new compatibility information is reported for ESMOLOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE, and METOPROLOL HYDROCHLORIDE, each in combination with 14 different drugs. Overall, new compatibility information is included for over 90 unique drug pairs in this supplement.

Fall 2016

In this supplement we added new drug monographs for DEFIBROTIDE SODIUM, CLEVIDIPINE, IPILIMUMAB, and POSACONAZOLE.

Also, we added new stability information for these drugs: AZACITIDINE, BENDAMUSTINE HYDROCHLORIDE, DEFEROXAMINE MESYLATE, DOXARUBICIN HYDROCHLORIDE, ERTAPENEM, GANCICLOVIR SODIUM, and MELPHALAN.

In addition new compatibility information is reported for LEVOFLOXACIN, MOXIFLOXACIN, NOREPINEPHRINE BITARTRATE, PIPERACILLIN AND TAZOBACTAM, TRAMADOL HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

Summer 2016

In this supplement we added new drug monographs for CANGRELOR (including compatibility information with 99 drugs), and for TEDIZOLID (including compatibility information with 86 drugs). Also, we added new stability information for fifteen drugs: ABCIXIMAB, ALFENTANIL HYDROCHLORIDE, ALTEPLASE, AZITHROMYCIN DIHYCLATE, BUPIVACAINE LIPOSOME, CO-TRIMOXAZOLE, DAPTOMYCIN, DIGOXIN, ERTAPENEM, MICAFUNGIN SODIUM, MILRINONE LACTATE, PROPOFOL, QUINUPRISTIN AND DALFOPRISTIN, ROPIVACAINE HYDROCHLORIDE and ZICONOTIDE. In addition new compatibility information is reported for BUPIVACAINE LIPOSOME AND ZICONOTIDE.

Spring 2016

In this supplement we added stability information for thirteen drugs: BETAMETHASONE SODIUM PHOSPHATE, CEFTAROLINE FOSAMIL, CETUXIMAB, COLISTIMETHATE SODIUM, ESOMEPRAZOLE SODIUM, GANCICLOVIR SODIUM, ISOPROTERENOL HYDROCHLORIDE, METOPROLOL TARTRATE, MICAFUNGIN SODIUM, MORPHINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, SODIUM PHOSPHATE and VASOPRESSIN.

In addition new compatibility information is reported for over thirty drug combinations, including: BETAMETHASONE SODIUM PHOSPHATE, BLEOMYCIN SULFATE, CALCIUM GLUCONATE, DAPTOMYCIN, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, KETOROLAC TROMETHAMINE, LEVOBUPIVACAINE, MORPHINE HYDROCHLORIDE, MAGNESIUM SULFATE, OXACILLIN SODIUM, PERITONEAL DIALYSIS SOLUTIONS, POTASSIUM PHOSPHATE, ROPIVACAINE HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

Winter 2015

In this supplement we added stability information for BENDAMUSTINE HYDROCHLORIDE, CHLOROTHIAZIDE SODIUM, FLUMAZENIL, PHYTONADIONE, and TELAVANCIN.

In addition new compatibility information is reported for BUTORPHANOL TARTRATE, DEXAMETHASONE SODIUM PHOSPHATE, DIPHENHYDRAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, ESOMEPRAZOLE SODIUM, FENTANYL CITRATE, FUROSEMIDE, GRANISETRON HYDROCHLORIDE, LORAZEPAM, METHADONE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, PIPERACILLIN AND TAZOBACTAM, VANCOMYCIN HYDROCHLORIDE, and VINCRISTINE SULFATE.

Fall 2015

In this supplement we added two new drug monographs with stability and compatibility information for BENDAMUSTINE HYDROCHLORIDE and NALMEFENE HYDROCHLORIDE. In addition new compatibility information is reported for AMIODARONE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, HEPARIN SODIUM, INSULIN, REGULAR, KETAMINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, NITROPRUSSIDE SODIUM, and SUFENTAIL CITRATE. Lastly, we added new stability information to these drug monographs: AMSACRINE, BLEOMYCIN SULFATE, CLONIDINE HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, FOSAPREPITANT DIMECLUMINE, and MEROPENEM.

Summer 2015

In this supplement we added one new drug monograph with stability and compatibility information for CABAZITAXEL. In addition new compatibility information is reported for CISATRACURIUM BESYLATE with nine other drugs, DOXAPRAM HYDROCHLORIDE with twelve other drugs, in addition to compatibility reports for twenty-five different two-drug combinations. Lastly, we added new stability information to these drug monographs: ASCORBIC ACID, BEVACIZUMAB, BORTEZOMIB, CEFTRIAXONE SODIUM, CISATRACURIUM BESYLATE, DAPTOMYCIN, DOCETAXEL, DOXAPRAM HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, EPOPROSTENOL SODIUM, ESMOLOL HYDROCHLORIDE, MEROPENEM, OMEPRAZOLE SODIUM, OXALIPLATIN, PROCAINAMIDE HYDROCHLORIDE, TREPROSTINIL SODIUM, and VASOPRESSIN.

Spring 2015

In this supplement we added three new drug monographs with stability and compatibility information for INSULIN GLARGINE, INSULIN GLULISINE, and ORITAVANCIN. In addition new compatibility information is reported for INSULIN ASPART with 47 other drugs, ORITAVANCIN with 37 other drugs, and ROCURONIUM BROMIDE with 20 other drugs. Lastly, we added new stability information to these drug monographs: AZATHIOPRINE SODIUM, CLONAZEPAM, DEXRAZOXANE, METHOHEXITAL SODIUM, MORPHINE HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE, and TRANEXAMIC ACID.

Winter 2014

We added new compatibility information for CALCIUM CHLORIDE, EPINEPHRINE HYDROCHLORIDE, CONIVAPTAN, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE, FUROSEMIDE, HEPARIN SODIUM, TOTAL PARENTERAL NUTRITION SOLUTIONS with 46 drugs, and ALPROSTADIL with 13 drugs. In addition, we added new stability information to these drug monographs: ALPROSTADIL, BUSULFAN, DAPTOMYCIN, ESOMEPRAZOLE SODIUM, FILGRASTIM, FLUDARABINE PHOSPHATE, FOLIC ACID, HYDROCORTISONE SODIUM SUCCINATE, PENICILLLIN G SODIUM, RIFAMPIN, and TOTAL PARENTERAL NUTRITION SOLUTIONS.

Fall 2014

We added new compatibility information for over 100 different parenteral drugs in combination with KETAMINE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE and MORPHINE SULFATE. In addition, we added new stability information to these drug monographs: ACETAZOLAMIDE SODIUM, ERTAPENEM, KETAMINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE, and ROCURONIUM BROMIDE.

Summer 2014

We added new compatibility information for over 100 different parenteral combinations, including numerous entries for these monographs: ACETAMINOPHEN, CIPROFLOXACIN, DIMENHYDRINATE, and VANCOMYCIN HYDROCHLORIDE.

In addition, we added new stability information to these drug monographs: BORTEZOMIB, CIPROFLOXACIN, DIMENHYDRINATE, DOCETAXEL, EPIRUBICIN HYDROCHLORIDE, GENTAMICIN SULFATE, GRANISETRON HYDROCHLORIDE, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, MELPHALAN, NALOXONE HYDROCHLORIDE, NITROGLYCERIN, OCTREOTIDE ACETATE, PIPERACILLIN AND TAZOBACTAM, PROTAMINE SULFATE, TICARCILLIN DISODIUM-CLAVULANATE POTASSIUM, VANCOMYCIN HYDROCHLORIDE, and VECURONIUM BROMIDE.

Spring 2014

We added new stability data to ten drug monographs, along with new information on over 50 different parenteral combinations, including entries in these monographs: AZACITIDINE, CEFAZOLIN SODIUM, CIPROFLOXACIN, CLOXACILLIN SODIUM, CYCLOSPORINE, KETAMINE HYDROCHLORIDE, MEROPENEM, METOCLOPRAMIDE HYDROCHLORIDE, MORPHINE SULFATE, NALOXONE HYDROCHLORIDE, PHENYTOIN SODIUM. RANITIDINE HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE

Winter 2013

This update provides new drug monographs for BUPIVACAINE LIPOSOME and SODIUM GLYCOLATE. In addition new information on over 150 different parenteral combinations is included, including entries in these monographs: ADENOSINE ALPROSTADIL AMPHOTERICIN B LIPOSOME DEXMEDETOMIDINE NALOXONE HYDROCHLORIDE NICARDIPINE HYDROCHLORIDE PAPAVERINE HYDROCHLORIDE PHENTOLAMINE MESYLATE PIPERACILLIN AND TAZOBACTAM POTASSIUM PHOSPHATE VANCOMYCIN HYDROCHLORIDE Also included is the addition of 3,300 new drug combinations.

Fall 2013

Included in this supplement are new drug monographs for IBUTILIDE FUMARATE and PERTUZUMAB. In addition we have included updates to the following existing monographs: ALDESLEUKIN AMPHOTERICIN B LIPOSOME CARBOPLATIN CEFEPIME HYDROCHLORIDE DILTIAZEM HYDROCHLORIDE ESMOLOL HYDROCHLORIDE MAGNESIUM SULFATE METOCLOPRAMIDE HYDROCHLORIDE MIDAZOLAM HYDROCHLORIDE PROPOFOL REMIFENTANIL HYDROCHLORIDE SODIUM CITRATE SODIUM BICARBONATE SUFENTANIL CITRATE TRAMADOL HYDROCHLORIDE TRASTUZUMAB.

Summer 2013

Boxed Warning, REMS, and Prescribing and Access Restriction Drugs have been identified and highlighted. Included in this supplement are new drug monographs for PROCHLORPERAZINE MESYLATE, RITUXIMAB, SILDENAFIL CITRATE, and TEMSIROLIMUS. In addition we have included new compatibility information for ACETAMINOPHEN with ten parenteral drugs, along with revisions to the following existing monographs: BEVACIZUMAB, CARMUSTINE, DOBUTAMINE HYDROCHLORIDE, GENTAMICIN SULFATE, LEVOFLOXACIN, MICAFUNGIN SODIUM, OXYCODONE HYDROCHLORIDE, SODIUM BICARBONATE, SODIUM CITRATE, and VANCOMYCIN HYDROCHLORIDE.

Winter 2012

Included in this supplement is a new drug monograph for CONIVAPTAN HYDROCHLORIDE. In addition we have included new compatibility information for SOTALOL HYDROCHLORIDE in combination with 32 other parenteral drugs, along with revisions to these existing monographs: CYTARABINE, DEXMEDETOMIDINE, EPOPROSTEROL SODIUM, FENTANYL CITRATE, GLOBULIN, IMMUNE (HUMAN), GLYCOPYRROLATE, HEPARIN SODIUM, INFLIXIMAB, MORPHINE SULFATE, TELAVANCIN, and VANCOMYCIN.

Fall 2012

Included in this supplement are new drug monographs for BEVACIZUMAB and CLOFARABINE. In addition we have included new compatibility and stability information for these existing monographs: ACETAMINOPHEN, BORTEZOMIB, CLINDAMYCIN PHPOSPHATE, DEXMEDETOMIDINE, FOSPHENYTOIN, INSULIN ASPART, INSULIN LISPRO, KETAMINE HYDROCHLORIDE, KETOPROFEN, KETOROLAC TROMETHAMINE, MIDAZOLAM HYDROCHLORIDE, PEMETREXED PROPOFOL, TRAMADOL HYDROCHLORIDE, TROPHAMINE, and VANCOMYCIN HYDROOCHLORIDE.

Summer 2012

Included in this supplement is a new drug monograph for TRASTUZUMAB. In addition we have included new compatibility and stability information for these existing monographs: ACETAMINOPHEN, CALCIUM CHLORIDE, CALCIUM GLUCONATE, CEFTAROLINE FOSAMIL, DOBUTAMINE HYDROCHLORIDE, DOCETAXEL, LEVOFLOXACIN, SODIUM BICARBONATE, and VINORELBINE TARTRATE.

Spring 2012

In this supplement is a new drug monograph for LEVOCARNITINE. In addition we have included new compatibility and stability information for these existing monographs: AMOXICILLIN-CLAVULANATE, CIPROFLOXACIN, HEPARIN SODIUM, HYDROMORPHONE HYDROCHLORIDE, MORPHINE SULFATE NICARDIPINE HYDROCHLORIDE, OCTREOTIDE LACTATE, and PANTOPRAZOLE SODIUM.

Winter 2011

Included in this supplement is a new drug monograph for KETOPROFEN. In addition we have included new information on the compatibility of ACETAMINOPHEN with twenty-eight other parenteral drugs. We have also added new compatibility and stability information to these existing monographs: AMIODARONE HYDROCHLORIDE, CYCLOSPORINE, ESMOLOL HYDROCHLORIDE, HEPARIN SODIUM, INSULIN, REGULAR, LABETALOL HYDROCHLORIDE, LEVOTHYROXINE SODIUM, NITROGLYCERIN, NITROPRUSSIDE SODIUM, NOREPINEPHRINE BITARTRATE, PANCURONIUM BROMIDE, PHENYLEPHRINE HYDROCHLORIDE, TERBUTALINE SUFATE, and VECURONIUM BROMIDE.

Fall 2011

Included in this supplement is a new drug monograph for TELAVANCIN that reports on its compatibility with 52 other parenteral drugs. In addition we have added new compatibility and stability information to these existing monographs: DEXRAZOXANE, DORIPENEM, DROPERIDOL, ERTAPENEM, FUROSEMIDE, IMIPENEM, INSULIN, METHOHEXITAL SODIUM, NOREPINEPHRINE BITARTRATE, PHENYLEPHRINE HYCRODHLORIDE, SODIUM BICARBONATE and VASOPRESSIN.

Summer 2011

Included in this supplement are new drug monographs for these parenteral drugs: ACETAMINOPHEN, LEVETIRACETAM, ARGININE HYDROCHLORIDE, MORPHINE TARTRATE, CEFTAROLINE FOSAMIL, PAMIDRONATE DISODIUM, EDETATE CALCIUM DISODIUM, and SODIUM THIOSULFATE. In addition we have added new compatibility and stability information to these existing monographs: ALPROSTADIL, AMIODARONE HYDROCHLORIDE, AMPHOTERICIN B, BUPIVACAINE HYDROCHLORIDE, CEFAZOLIN SODIUM, DILTIAZEM HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, FENTANYL CITRATE, GENTAMICIN SULFATE, HEPARIN SODIUM KETAMINE HYDROCHLORIDE, MICAFUNGIN, MORPHINE SULFATE, ONDANSETRON HYDROCHLORIDE, SODIUM BICARBONATE, SODIUM CITRATE, VANCOMYCIN HYDROCHLORIDE, ZICONOTIDE, and VASOPRESSIN.

Winter 2010

Included in this supplement are new drug monographs for these parenteral drugs: HYOSCINE BUTYLBROMIDE SODIUM CITRATE TEICOPLANIN In addition we have added new compatibility and stability information to these existing monographs: AMIKACIN SULFATE, CASPOFUNGIN ACETATE, CIPROFLOXACIN, DAPTOMYCIN, FLUOROURACIL, HALOPERIDOL LACTATE, HEPARIN SODIUM, KETAMINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE, LINEZOLID, MORPHINE SULFATE, TRAMADOL HYDROCHLORIDE, and VANCOMYCIN HYDROCHLORIDE.

Fall 2010

Included in this supplement are new drug monographs for these parenteral drugs: ACETYLCYSTEINE, CLINIMIX INJECTIONS, OFATUMUMAB, ROMIDEPSIN, and TELAVANCIN. In addition we have added new compatibility and stability information to these existing monographs: AMIODARONE HYDROCHLORIDE, CEFTAZIDIME, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, FUROSEMIDE, HYDROMORPHONE HYDROCHLORIDE, NITROGLYCERINE, PANCURONIUM BROMIDE, PIPERACILLIN AND TAZOBACTAM, and SODIUM BICARBONATE.

Summer 2010

Included in this supplement are new drug monographs for these parenteral drugs: CETUXIMAB, INFLIXIMAB, PANITUMUMAB, and SOTALOL HYDROCHLORIDE. In addition we have added new compatibility and stability information to these existing monographs: DAPTOMYCIN, DILTIAZEM HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, DORIPENEM, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, MAGNESIUM SULFATE, MESNA, NITROPRUSSIDE SODIUM, SODIUM BICARBONATE, and TERBUTALINE SULFATE.

Spring 2010

This update includes our first original research for the drugs: ATROPINE SULFATE and PANCURONIUM BROMIDE. This information can only be found in the King Guide. Also, included in this supplement are new drug monographs for these parenteral drugs: BORTEZOMIB and IRON SUCROSE. In addition we have added new compatibility and stability information to these existing monographs: ATROPINE SULFATE, CEFEPIME HYDROCHLORIDE, DIMENHYDRINATE, GANCICLOVIR, HALOPERIDOL LACTATE, INSULIN, REGULAR, IRONOTECAN HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, MORPHINE HYDROCHLORIDE, MORPHINE SULFATE, NOREPINEPHRINE BITARTRATE, RANITIDINE HYDROCHLORIDE, SODIUM BICARBONATE, TACROLIMUS, TRAMADOL and TRANEXAMIC ACID.

Winter 2009

Included in this supplement are new drug monographs for these parenteral drugs: ALEMTUZUMAB, AMPHOTERICIN B LIPOSOME, IBUPROFEN, and INSULIN LISPRO. In addition we have added new compatibility and stability information to these existing monographs: ARIPIPRAZOLE, BUSULFAN, DALTEPARIN SODIUM, EPTIFIBATIDE, METOPROLOL TARTRATE, NEOSTIGMINE METHYLSULFATE, NESIRITIDE, OXALIPLATIN, PALONOSETRON HYDROCHLORIDE, PERITONEAL DIALYSIS SOLUTIONS, PROPOFOL, and VANCOMYCIN HYDROCHLORIDE.

Fall 2009

We have added new compatibility and stability information to these monographs: ACYCLOVIR SODIUM, AMIODARONE, CAFFEINE CITRATE, CYCLOSPORINE, LEVOFLOXACIN, MEROPENEM, and VANCOMYCIN.

Fall 2009

We have added new compatibility and stability information to these monographs: ACYCLOVIR SODIUM, AMIODARONE, CAFFEINE CITRATE, CYCLOSPORINE, LEVOFLOXACIN, MEROPENEM, and VANCOMYCIN.

Summer 2009

We have added new monographs for these parenteral products: ESOMEPRAZOLE SODIUM, MOXIFLOXACIN HYDROCHLORIDE, and ZICONOTIDE. We have also added new compatibility and stability information to these monographs: AMIODARONE HYDROCHLORIDE, ATROPINE SULFATE, MORPHINE SULFATE, MORPHINE HYDROCHLORIDE, OCTREOTIDE ACETATE, OMEPRAZOLE SODIUM, PRALIDOXIME CHLORIDE, and TRAMADOL HYDROCHLORIDE.

Spring 2009

We have added stability and compatibility information for these parenteral products: ANIDULAFUNGIN, NOREPINEPHRINE BITARTRATE, and SUCCINYLCHOLINE CHLORIDE. The new information for ANIDULAFUNGIN includes admixture compatibility data in combination with 77 different parenteral products.

Winter 2008

FAMOTIDINE, HEPARIN SODIUM, LIDOCAINE HYDROCHLORIDE, MICAFUNGIN SODIUM, PAPAVERINE HYDROCHLORIDE, SODIUM BICARBONATE, and TIGECYCLINE. The new information for MICAFUNGIN includes admixture compatibility data for MICAFUNGIN in combination with 49 different parenteral products. And, a new monograph for TIGECYCLINE has also been included in the enclosed Supplement.

Fall 2008

We have added stability and compatibility information for these parenteral products: CASPOFUNGIN ACETATE, METRONIDAZOLE, and PALONOSETRON HYDROCHLORIDE. Included are the results of admixtures compatibility studies of these three parenterals in combination with over 80 other drug products.

Summer 2008

We have added stability and compatibility information for these drug products: DORIPENEM, EPIRUBICIN, LEVOBUPIVACAINE, and VORICONAZOLE. We are also reporting new results of stability studies for DAPTOMYCIN.

Spring 2008

We have added stability information for one new drug product: PANTOPRAZOLE. We are also reporting the results of compatibility studies for PANTOPRAZOLE in admixture with 90 parenteral products including: CASPOFUNGIN ACETATE, CIPROPLOXACIN, ENALAPRILAT, FLUCONAZOLE, LEVOFLOXACIN, MEROPENEM, PROPOFOL, VASOPRESSIN, and ZIDOVUDINE. Also included in the enclosed supplement is additional compatibility information for CEFTRIAXONE used with calcium-containing products.

Winter 2007

We have updated important new medication safety information on CEFTRIAXONE SODIUM, as reported by the U.S. Food and Drug Administration. We have added stability and compatibility information for one new drug product: CELLCEPT®. Also included is compatibility information for CASPOFUNGIN ACETATE, ALFENTANIL HYDROCHLORIDE, and CEFTAZIDIME in combination with numerous other parenteral drugs.

Fall 2007

We have added important new medication safety information on CEFTRIAXONE SODIUM, as reported by the U.S. Food and Drug Administration. We have also added stability and compatibility information for three new drug products: ARIPIPRAZOLE, CASPOFUNGIN ACETATE, and ROPIVACAINE HYDROCHLORIDE. Also included in this update are compatibility information for CEFEPIME, GANCICLOVIR, KETAMINE, KETOROLAC, and NESIRITIDE.

Summer 2007

We have added compatibility information for one new drug product: OXALIPLATIN. Included in this new drug monograph is compatibility information for over 50 different parenteral drug combinations, including: Bumetanide, Docetaxel, Dolasetron Mesylate, Enalaprilat, Gemcitabine Hydrochloride, Leucovorin Calcium, Ondansetron Hydrochloride, Paclitaxel, Ranitidine Hydrochloride, Topotecan Hydrochloride, and Verapamil Hydrochloride. The results of stability studies on PALONOSETRON HYDROCHLORIDE with CISPLATIN, CARBOPLATIN, METOCLOPRAMIDE HYDROCHLORIDE, and PROMETHAZINE HYDROCHLORIDE are also included in our 2007 Summer Supplement.

Spring 2007

We have added compatibility information for two new drug products: Piperacillin and Tazobactam, and Pemetrexed. Included in these two new drug monographs are compatibility information for over 80 different parenteral drug combinations, including: amifostine, amikacin, aztreonam, carboplatin, ciprofloxacin, dexrazoxane, docetaxel, doxorubicin, gentamicin, granisetron, irinotecan, ranitidine, topotecan, and zidovudine.

Winter 2006

We have added compatibility information for two new drugs: Nesiritide in combination with 30 different drugs, and infusion stability data for Insulin Aspart. In addition we have provided additional information for these existing drug monographs: Oxytocin, Palonosetron, Dacarbazine, Cefuroxime, and Leucovorin Calcium.

Fall 2006

We have added compatibility information for Lansoprazole in combination with seventy-eight different parenteral products including the following: Acyclovir, Gemcitabine, Alatrofloxacin, Gentamicin, Ceftriaxone, Labetalol, Cyclosporine, Midazolam, Droperidol, Morphine, Enalaprilat, Nicardipine, Etoposide, Paclitaxel, Famotidine, Ranitidine, Fentanyl, Vinorelbine, Ganciclovir, and Zidovudine.

Summer 2006

We have added compatibility information for a new drug, Lansoprazole. Also included are new data on the compatibility and stability of these drugs: Clonidine Hydrochloride, Fentanyl Citrate, Morphine Sulfate, Hydralazine Hydrochloride, and Vasopressin.

Spring 2006

We have added a new drug monograph, DEXMEDETOMIDINE HYDROCHLORIDE (PRECEDEX®), in this supplement. Over 90 different drugs were tested with this drug, including: Alfentanil, Amiodarone, Azithromycin, Aztreonam, Bretylium, Cefepime, Cimetidine, Dobutamine, Dolasetron, Enalaprilat, Esmolol, Famotidine, Gatifloxacin, Inamrinone, Ketorolac, Linezolid, Milrinone, Ofloxacin, Ondansetron, Propofol, Ranitidine, Sufentanil, Vancomycin, and Verapamil.

Winter 2005

We have added a new drug monograph, Tramadol Hydrochloride, in this supplement. Also included is new information for 46 different drugs including entries for these parenteral products: Argatroban, Cidofovir, Clonidine Hydrochloride, Dolasetron Mesylate, Doxorubicin Hydrochloride, Droperidol, Fentanyl Citrate, Gentamicin Sulfate, Ketamine Hydrochloride, Ketorolac Tromethamine, Levofloxacin, Lorazepam, Morphine Sulfate, Ondandestron Hydrochloride, Palonosetron Hydrochloride, Vancomycin Hydrochloride, and Zidovudine.

Fall 2005

Included in this supplement are new information for Bivalirudin, Fenoldopam Mesylate, and Teniposide in combination with dozens of other parenteral drug products. In addition, we have added monographs for Codeine Sulfate, Ammonium Chloride, and Amobarbital.

Summer 2005

Included in this Supplement are compatibility data for one new drug monograph, Drotrecogin Alfa, in combination with thirty-four different parenteral medications. Also included are compatibility data for Argatroban in combination with total parenteral nutrition solutions and with these drugs: Amiodarone hydrochloride, Furosemide, Fenoldopam Mesylate, Lidocaine Hydrochloride, Milrinone Lactate, Nitroglycerin, Nitroprusside Sodium, and Vasopressin.

Spring 2005

Included in this Supplement are compatibility data for two new drug monographs: Daptomycin and Palonosetron Hydrochloride. In addition we have added new information to these existing monographs: Co-Trimoxazole, Fluorouracil, Furosemide, Inamrinone Lactate, Levofloxacin, Nitroglycerin, Norepinephrine Bitartrate, Ondansetron Hydrochloride, and Potassium Phosphate.